Literature DB >> 19956913

Chromosome 1p and 19q evaluation in low-grade oligodendrogliomas: a descriptive study.

Chiara Molinari1, Paolo Iorio, Laura Medri, Michela Ballardini, Graziano Guiducci, Anna Maria Cremonini, Serenella Cerasoli, Luca Riccioni, Marina Faedi, Giulia Adalgisa Mariani, Wainer Zoli, Rosella Silvestrini, Danielle Calistri.   

Abstract

Oligodendrogliomas are rare primary brain tumors with variable patient outcomes which are not always adequately accounted for by clinical or pathological variables. The present study evaluated the prognostic implications of chromosome 1p and 19q status in a set of 23 low grade oligodendrogliomas (OGD II), and correlated the results with patient outcome. Loss of heterozygosity (LOH) and fluorescent in situ hybridization (FISH) analyses, the most widely used standard procedures, were used. 1p and 19q deletions were found in 65 and 61% of cases, respectively, using FISH and in 78 and 72% of cases using LOH. Both deletions were found in 56 and 64% of patients using FISH and LOH, respectively. Concordance between the results from the two techniques, determined by the Kappa statistics, ranged from fair to substantial depending on whether single or combined deletions were considered. Our results showed that the molecular alterations are associated with age and tumor localization. With regard to the impact of chromosomal alterations on clinical outcome, chromosome 19q deletions detected by LOH would seem to indicate a subgroup of patients at a higher risk of relapse, although the small number of patients recruited does not permit any definitive conclusions to be drawn. Further studies are now ongoing to determine whether this methodological approach could be potentially useful in low grade oligodendrogliomas to better characterize chromosomal alterations of 1p/19q and identify subgroups of patients with a higher risk of disease recurrence.

Entities:  

Mesh:

Year:  2010        PMID: 19956913

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

Review 1.  Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Authors:  Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

2.  Moving toward molecular classification of diffuse gliomas in adults.

Authors:  Brett J Theeler; W K Alfred Yung; Gregory N Fuller; John F De Groot
Journal:  Neurology       Date:  2012-10-30       Impact factor: 9.910

3.  Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization.

Authors:  Jongmin Sim; Do-Hyun Nam; Yuil Kim; In-Hee Lee; Jung Won Choi; Jason K Sa; Yeon-Lim Suh
Journal:  Med Oncol       Date:  2018-03-29       Impact factor: 3.064

4.  Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.

Authors:  Céline Duval; Marie de Tayrac; Karine Michaud; Florian Cabillic; Claudie Paquet; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

5.  A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.

Authors:  Rebecca Senetta; Ludovica Verdun di Cantogno; Luigi Chiusa; Isabella Castellano; Patrizia Gugliotta; Anna Sapino; Paola Cassoni
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

6.  Identification of a panel of genes as a prognostic biomarker for glioblastoma.

Authors:  Fengfei Wang; Zheng Zheng; Jitian Guan; Dan Qi; Shuang Zhou; Xin Shen; Fushun Wang; David Wenkert; Batool Kirmani; Touradj Solouki; Ekokobe Fonkem; Eric T Wong; Jason H Huang; Erxi Wu
Journal:  EBioMedicine       Date:  2018-10-16       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.